EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Rhea-AI Summary

On November 10, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced four abstracts featuring its products YUTIQ® and DEXYCU® presented at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting from November 13-15, 2020.

The presentations include:

• YUTIQ: Phase 3 trial results showing 36-month anti-inflammatory activity.
• DEXYCU: Studies on patient preference and anti-inflammatory efficacy.

These advancements underline EyePoint's commitment to innovative ophthalmic solutions.

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for presentation at the upcoming American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting, taking place November 13-15, 2020.

Details for the AAO presentations are as follows:

Paper Presentation

Second Phase 3 trial of YUTIQ shows durable 36-month anti-inflammatory activity for difficult to treat ocular disease
Title: FAi Insert Treatment for Noninfectious Posterior Uveitis: Three-Year Results of a Confirmatory Trial
Presenter: Glenn J. Jaffe, M.D., Robert Machemer M. D. Distinguished Professor of Ophthalmology, Duke University School of Medicine
Session: PA063
Date and time: Available on demand Nov 14-15, 2020

Poster Presentations

Investigator-sponsored study demonstrates patient preference of DEXYCU and a “minimum eye drop” regimen
Title: The D3 Study: Drug Delivery vs. Drops—A Prospective Clinical Study Evaluating Dexycu vs. Prednisolone Acetate 1% in Controlling Postoperative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery
Presenter: John A. Hovanesian, M.D., Specialist in Cataract, Refractive, Cornea and Pterygium Surgery, Harvard Eye Associates
Session: PO049
Date and time: Available on demand Nov 14-15, 2020

Real-world data of DEXYCU highlights durable anti-inflammatory activity and results comparable to Phase 3 clinical trials
Title: Dexamethasone Intraocular Suspension 9% After Cataract Surgery: Data From a Retrospective Study
Presenter: Robert J. Weinstock, M.D., Director of Cataract and Refractive Surgery, The Eye Institute of West Florida and the Weinstock Laser Eye Center
Session: PO050
Date and time: Available on demand Nov 14-15, 2020

Real world data of DEXYCU shows strong anti-inflammatory efficacy with and without additional topical anti-inflammatory treatment
Title: Outcomes With Dexamethasone Intraocular Suspension 9% and Concomitant Postoperative Anti-inflammatory Medications
Presenter: Cynthia Matossian, M.D., Founder and Chief Executive Officer, Matossian Eye Associates
Session: PO051
Date and time: Available on demand Nov 14-15, 2020

About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for wet age-related macular degeneration. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contacts
Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
eyepoint@argotpartners.com

Media:
Thomas Gibson
201-476-0322
tom@tomgibsoncommunications.com

FAQ

What did EyePoint Pharmaceuticals announce on November 10, 2020?

EyePoint Pharmaceuticals announced that four abstracts on YUTIQ® and DEXYCU® were selected for presentation at the AAO 2020 Virtual Annual Meeting.

When is the AAO 2020 Virtual Annual Meeting?

The AAO 2020 Virtual Annual Meeting is taking place from November 13-15, 2020.

What are the main topics of the presentations about YUTIQ® and DEXYCU®?

The presentations focus on YUTIQ's long-term anti-inflammatory results and DEXYCU's patient preference and efficacy.

Who presented the YUTIQ® Phase 3 trial results?

The YUTIQ® Phase 3 trial results were presented by Glenn J. Jaffe, M.D.

What significance does the DEXYCU® study hold?

The DEXYCU® studies provide real-world data on anti-inflammatory activity and patient preference for treatment.